RxDoctor Payments DataLook up a doctor →

Mohit Narang, MD

Medical Oncology · Owing Mills, MDNPI 1881695351

Payments from drug & device makers

$4,731,289in general payments, 2019–2025

Across 2,822 payments — averaging $1676.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$971K
  • Amgen$488K
  • Genentech, Inc.$355K
  • F. Hoffmann-la Roche AG$286K
  • Bristol Myers Squibb$278K
  • Takeda Pharmaceuticals U.S.A., Inc.$250K
  • plus $2.1M from 54 others
$11,416in research payments, 2019–2025

Across 2 payments — averaging $5708.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bristol Myers Squibb$10K
  • Acerta Pharma LLC$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.212$970,591
Amgen23$488,183
Genentech, Inc.83$355,286
F. Hoffmann-la Roche AG39$285,922
Bristol Myers Squibb132$278,327
Takeda Pharmaceuticals U.S.A., Inc.80$250,384
Incyte Corporation243$188,559
Beigene USA, Inc.130$181,766
Johnson & Johnson(2 entities)229$179,656
Morphosys AG153$161,252
TG Therapeutics, Inc.106$141,836
Janssen Research & Development, LLC281$120,095
Daiichi Sankyo Inc.110$111,620
Beigene, Ltd.37$102,242
Rigel Pharmaceuticals, Inc.83$90,697
Exelixis Inc.50$83,557
Beone Medicines USA, Inc.47$79,284
Hoffmann-la Roche Limited16$79,092
Pharmacosmos Therapeutics Inc.53$72,734
Eisai Inc.64$54,502
Mirati Therapeutics, Inc.8$51,284
GSK32$41,962
Genmab U.S., Inc.32$40,209
Karyopharm Therapeutics Inc.57$37,618
Blueprint Medicines Corporation17$30,416
AbbVie50$29,805
Novocure Inc.29$23,746
Bayer19$22,138
Stemline Therapeutics Inc.18$21,707
Pharmacyclics LLC, An Abbvie Company34$21,372
AstraZeneca(2 entities)20$19,968
Acerta Pharma LLC4$17,647
Pharmaessentia USA Corporation20$17,280
Avyxa Pharma, LLC9$8,775
Morphosys, US Inc.11$7,768
American Regent1$7,200
Regeneron Healthcare Solutions, Inc.16$6,715
Sanofi12$6,194
Taiho Oncology, Inc.7$5,660
Seagen Inc.9$5,481
Novartis62$5,224
Genentech USA, Inc.21$4,981
Gilead(2 entities)13$4,230
Sumitomo Pharma America, Inc.5$3,027
Global Blood Therapeutics, Inc.2$3,006
Ipsen Biopharmaceuticals, Inc2$2,233
Eli Lilly1$2,188
Pfizer41$1,861
Sanofi US Services Inc.2$1,603
Immunomedics, Inc.1$1,000
Adaptive Biotechnologies Corporation2$764
Merck22$688
AVEO Pharmaceuticals, Inc.10$322
Lilly USA, LLC4$168
Astellas Pharma US Inc7$131
Eagle Pharmaceuticals, Inc.1$128
Sobi, Inc5$112
Clovis Oncology, Inc.1$100
Spectrum Pharmaceuticals Inc.4$95
Dendreon Pharmaceuticals LLC4$90

How this compares

$4,731,289 in reported general payments places this provider in the 90th percentile of 180 medical oncology providers in Maryland.

See all medical oncology providers in Maryland →

Medicare billing

Part B allowed, 2024
$6,606,504
Medicare patients
1,480
Services billed
284,445

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Owing Mills

See the full list for Maryland →

Where these figures come from

Is this you, or does something look wrong? →